AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 35477618
Drug: Amphetamine Extended-Release
RxNorm normalized name: amphetamine Extended Release Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amphetamine Extended-Release Tablet (AMPH ER TAB) 5 mg starting dose, titrated to 20 mg
Trial: 35801274
Drug: Polymyxin B
RxNorm normalized name: Polymyxin B
DrugBank: Polymyxin B (DB00781)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Polymyxin B (PolyB 6000 IU/kg IV, 7 doses q12h)
Trial: 35801274
Drug: Polymyxin B/gentamicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polymyxin B/gentamicin (PolyB 6000 IU/kg IV, q12h 7 doses; gentamicin 10 mg/kg IV q24h 4 doses)
Trial: 35417771
Drug: Brief Intervention‐Medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brief Intervention‐Medication Therapy Management (BI‐MTM)
Trial: 32461125
Drug: Intradiscal injection
RxNorm normalized name: Valrubicin Intravesical Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradiscal injection of glucocorticoids (50mg prednisolone acetate), n=24
Trial: 32461125
Drug: Intradiscal injection
RxNorm normalized name: Valrubicin Intravesical Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradiscal injection of lidocaine (40mg), n=26
Trial: 34025075
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment group (30-g or 60-g superdonor faeces)
Trial: 33791095
Drug: Amoxicillin treatment
RxNorm normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amoxicillin treatment (duration not specified)
Trial: 32655260
Drug: Radical resection
RxNorm normalized name: Campsis radicans flower extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radical resection combined with postoperative adjuvant chemotherapy
Trial: 36137731
Drug: Rehabilitation therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rehabilitation therapy plus optional delayed ACL reconstruction (n=82)
Trial: 33225615
Drug: Oxytocin (24-IU
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxytocin (24-IU single-dose intranasal)
Trial: 33731168
Drug: Bone turnover
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bone turnover marker (BTM) monitoring with alendronate, calcitriol, and calcium; medication duration was prolonged based on BTM results.
Trial: 33731168
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group received oral medication (alendronate, calcitriol, and calcium) for a uniform duration of 3 months.
Trial: 32934804
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg nefopam before surgical incision and normal saline before the end of surgery (Nefopam-Placebo)
Trial: 32934804
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline before surgical incision and 30 mg of nefopam before the end of surgery (Placebo-Nefopam)
Trial: 32934804
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg nefopam in both timings (Nefopam-Nefopam)
Trial: 33571293
Drug: Cannabis (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cannabis (0.5 g dried cannabis flowers with 80 mg THC)
Trial: 32468687
Drug: Nutrition education
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nutrition education intervention (four nutrition classes and monthly home visits by cadres)
Trial: 32468687
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (standard monthly health care at the health post)
Trial: 36241511
Drug: Single-dose groups
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose groups
Trial: 34329337
Drug: HD-MAP with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HD-MAP with 15 μg HA
Trial: 32304710
Drug: Vancomycin group
RxNorm normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vancomycin group (pre-soaked in 5mg/ml vancomycin for 10 minutes)
Trial: 34321092
Drug: Walking prescription
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Walking prescription of 150 min/week during pre-surgical waiting time
Trial: 36237582
Drug: Shuanghuanghua granules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shuanghuanghua granules (ultrafine preparation)
Trial: 36237582
Drug: Shuanghuanghua granules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shuanghuanghua granules (extract preparation)
Trial: 32395750
Drug: Modified natural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified natural cycle frozen embryo transfer (modified NC-FET) with subcutaneous hCG injection to trigger ovulation
Trial: 35907978
Drug: Methotrexate (concomitant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methotrexate (concomitant treatment)
Trial: 33560052
Drug: Telmisartan 80
RxNorm normalized name: telmisartan 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telmisartan 80 mg/day (n=2903)
Trial: 33560052
Drug: Ramipril 10
RxNorm normalized name: ramipril 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ramipril 10 mg/day (n=8407)
Trial: 33560052
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of telmisartan 80 mg/day and ramipril 10 mg/day (n=8334)
Trial: 34809689
Drug: Fermented Rhus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fermented Rhus verniciflua Stokes extract (FRVE) - 129 mg fustin and 59 mg fisetin, taken as two capsules once daily for 12 weeks
Trial: 34809689
Drug: Placebo (lactose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (lactose 627.0 mg), taken as two capsules once daily for 12 weeks
Trial: 37353654
Drug: Endoscopic vacuum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endoscopic vacuum therapy (EVT)
Trial: 35482987
Drug: Reishimmune-S 500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reishimmune-S 500 mg/day orally for 14 days
Trial: 36356657
Drug: Efzofitimod 1
RxNorm normalized name: Efzofitimod
DrugBank: Efzofitimod (DB16453)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Efzofitimod 1 mg/kg
Trial: 36356657
Drug: Efzofitimod 3
RxNorm normalized name: Efzofitimod
DrugBank: Efzofitimod (DB16453)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Efzofitimod 3 mg/kg
Trial: 36356657
Drug: Efzofitimod 5
RxNorm normalized name: Efzofitimod
DrugBank: Efzofitimod (DB16453)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Efzofitimod 5 mg/kg
Trial: 36356657
Drug: Efzofitimod 3
RxNorm normalized name: Efzofitimod
DrugBank: Efzofitimod (DB16453)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Efzofitimod 3 mg/kg and 5 mg/kg
Trial: 34411627
Drug: 15 µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 µg fentanyl with 10 mg hyperbaric bupivacaine
Trial: 34411627
Drug: 10 µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 µg fentanyl with 10 mg hyperbaric bupivacaine
Trial: 34411627
Drug: 7.5 µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.5 µg fentanyl with 10 mg hyperbaric bupivacaine
Trial: 34411627
Drug: 0 µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 µg fentanyl with 10 mg hyperbaric bupivacaine (Control Group IV)
Trial: 32324238
Drug: High-dose azithromycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose azithromycin (20 mg/kg/d)
Trial: 32324238
Drug: Standard-dose azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Standard-dose azithromycin (10 mg/kg/d)
Trial: 32174296
Drug: Cognitive behaviour
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behaviour therapy adapted for health anxiety (CBT-HA)
Trial: 34607194
Drug: Individual Opioid
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Individual Opioid Drug Counseling (ODC) plus buprenorphine
Trial: 36228577
Drug: Multimodal treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multimodal treatment (MT)
Trial: 36228577
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of multimodal treatment with aerobic training (CT)
Trial: 32532299
Drug: Females with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Females with borderline high and above total cholesterol (TC ≥ 200 mg/dL)
Trial: 32532299
Drug: Females with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Females with borderline high and above triglycerides (TG ≥ 150 mg/dL)
Trial: 32532299
Drug: Females with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Females with borderline high and above low-density lipoprotein cholesterol (LDL-C ≥ 130 mg/dL)
Trial: 32532299
Drug: Females with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Females with low high-density lipoprotein cholesterol (HDL-C < 40 mg/dL)
Trial: 35491518
Drug: GIPR antagonist
RxNorm normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: GIPR antagonist GIP(3‐30)NH2 (1,200 pmol/kg/min) with GLP‐1 infusion (0.75 pmol/kg/min)
Trial: 35491518
Drug: GIPR antagonist
RxNorm normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: GIPR antagonist GIP(3‐30)NH2 with GLP‐1 infusion
Trial: 35706870
Drug: Selenium 400
RxNorm normalized name: selenium 400 MCG in 10 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selenium 400 μg tablets, taken three times a week after each hemodialysis session for 3 months
Trial: 34011404
Drug: Protective ventilation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protective ventilation group with tidal volume (VT) of 7 ml/kg of predicted body weight (PBW) and optimal PEEP
Trial: 34011404
Drug: Traditional ventilation
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Traditional ventilation group with tidal volume (VT) of 9 ml/kg of predicted body weight (PBW)
Trial: 34686780
Drug: selective internal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: selective internal radiation therapy
Trial: 33130569
Drug: Psychosexual education
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychosexual education about medical and behavioural treatment options for sexual dysfunction delivered by a haematology nurse consultant; emotionally focused therapy-based relationship education programme for couples delivered by a clinical psychologist (four sessions of 1.5 hours each).
Trial: 32607598
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg riluzole
Trial: 33767247
Drug: Traditional Medicine
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional Medicine
Trial: 32050105
Drug: Local antibiotic
RxNorm normalized name: RECTAL,LOCAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local antibiotic therapy (LAT) with metronidazole gel
Trial: 37178435
Drug: Oral Semaglutide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Semaglutide
Trial: 32788083
Drug: G-MEDSS (Computerised
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-MEDSS (Computerised Clinical Decision Support System)
Trial: 32788083
Drug: G-MEDSS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-MEDSS
Trial: 36085067
Drug: Progressive Goal
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Progressive Goal Attainment Program (PGAP) intervention consisting of a maximum of 10 weekly individual sessions provided by a trained PGAP professional.
Trial: 35612866
Drug: Apixaban (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apixaban (5 mg or 2.5 mg twice daily)
Trial: 33386831
Drug: Myoelectrically controlled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Myoelectrically controlled FES (MeCFES) followed by robotic therapy (MRG)
Trial: 33542427
Drug: Individual dose-volume
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Individual dose-volume histograms (IDVHs) method for PTV DVH prediction
Trial: 33542427
Drug: Distance-to-target histogram
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Distance-to-target histogram and conformal-plan-dose-volume histogram (DTH + CPDVH) method for OAR DVH prediction
Trial: 34709859
Drug: Countermarketing and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Countermarketing and water promotion messages combined (combination group)
Trial: 33737346
Drug: Current treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Current treatment based on CTCAE grading
Trial: 35088231
Drug: Nivolumab plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab plus standard chemotherapy
Trial: 35076138
Drug: Intraarticular injections
RxNorm normalized name: dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intraarticular injections with 20 mg gold microparticles
Trial: 33369870
Drug: Intratympanic (IT)
RxNorm normalized name: ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intratympanic (IT) dexamethasone administered once every other day for 24 days
Trial: 33369870
Drug: Intravenous (IV)
RxNorm normalized name: intravenous (IV) infusion pump
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (IV) dexamethasone for 12 days followed by IT dexamethasone once every other day for 12 days
Trial: 33309460
Drug: Intranasal oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal oxytocin (24 IU, once daily for four weeks)
Trial: 36457059
Drug: ceftolozane/tazobactam (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ceftolozane/tazobactam (3 g [2 g ceftolozane/1 g tazobactam] every 8 h)
Trial: 36457059
Drug: meropenem (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: meropenem (1 g every 8 h)
Trial: 35963558
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment (d-methylphenidate and guanfacine)
Trial: 32965476
Drug: Clopidogrel plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel plus aspirin (dual antiplatelet therapy) for 3 months
Trial: 32965476
Drug: Aspirin plus
RxNorm normalized name: Aspirin Plus Antacid Extra Strength
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin plus placebo (single antiplatelet therapy) for 3 months
Trial: 33801537
Drug: Mobile mental
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mobile mental health apps based on cognitive behavior theory, stress theory, and ecological instant intervention theory (including breathing training, meditation, and music therapy)
Trial: 32649395
Drug: Active group
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active group music therapy program (3 months, twice per week, 60 minutes per session)
Trial: 32649395
Drug: Daily activities
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily activities (comparison group)
Trial: 34124927
Drug: Standard clinic-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard clinic-based cognitive behavioral therapy (S-CBT)
Trial: 34124927
Drug: Minimal therapist
RxNorm normalized name: Centipeda minima whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minimal therapist contact cognitive behavioral therapy (MC-CBT)
Trial: 36495477
Drug: Patients who
RxNorm normalized name: MAYZENT 0.25mg Tablet Starter Pack (For Patients Who Will Receive The 2mg Maintenance Dosage)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients who received an opioid prescription prior to but not after OUD diagnosis
Trial: 33525270
Drug: 0.3g/Kg of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3g/Kg of a glucose preparation
Trial: 32615837
Drug: ‘ward’ vaginal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ‘ward’ vaginal tablet containing 200 mg of dried extract applied vaginally for 7 consecutive nights
Trial: 33422263
Drug: Continuation of
RxNorm normalized name: varenicline
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continuation of renin–angiotensin system inhibitors
Trial: 33422263
Drug: Discontinuation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Discontinuation of renin–angiotensin system inhibitors
Trial: 33031764
Drug: Lopinavir-ritonavir (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lopinavir-ritonavir (400 mg and 100 mg, respectively) by mouth for 10 days or until discharge
Trial: 33082286
Drug: 60 mL
RxNorm normalized name: Disposable Nurser 60 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mL 0.375% ropivacaine
Trial: 33082286
Drug: 60 mL
RxNorm normalized name: Disposable Nurser 60 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mL isotonic saline (placebo)
Trial: 613168068
Drug: Nicotinamide (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotinamide (300 mg)
Trial: 613168068
Drug: Nicotinic acid
RxNorm normalized name: Nicotinic acid
DrugBank: Niacin (DB00627)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotinic acid (300 mg)
Trial: 34953155
Drug: Rosuvastatin 20
RxNorm normalized name: rosuvastatin 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosuvastatin 20 mg/day for 28 days
Trial: 35447502
Drug: Intravenous calcium
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous calcium chloride (1 gram)
Trial: 33834863
Drug: Fufang E’jiao
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fufang E’jiao Syrup (FFEJS), 20 ml, 3 times a day for 6 weeks
Trial: 33834863
Drug: Placebo, 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, 20 ml, 3 times a day for 6 weeks
Trial: 33834863
Drug: Fufang E’jiao
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fufang E’jiao Syrup (FFEJS)
Trial: 34295831
Drug: Adjunctive probiotic
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjunctive probiotic group (Lacticaseibacillus rhamnosus GR‐1 and Limosilactobacillus reuteri RC‐14 orally for 30 days)
Trial: 34295831
Drug: Metronidazole group
RxNorm normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Metronidazole group (metronidazole vaginal suppositories for 7 days)
Trial: 34295831
Drug: Adjunctive probiotic
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjunctive probiotic group
Trial: 36944848
Drug: Lapatinib (L)
DrugBank: Lapatinib (DB01259)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Lapatinib (L)
Trial: 35238305
Drug: Melatonin (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin (3 mg/day for 7 days)
Trial: 33640423
Drug: Proton therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proton therapy (PT)
Trial: 33044178
Drug: HP‐EH‐EVOO (50 mL/day)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HP‐EH‐EVOO (50 mL/day)
Trial: 33044178
Drug: MP‐EVOO (50 mL/day)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MP‐EVOO (50 mL/day)
Trial: 39054467
Drug: Pembrolizumab monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab monotherapy
Trial: 35389559
Drug: Prosthesis buccal
RxNorm normalized name: LARYNGEAL PROSTHESIS,PROVOX #8273
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prosthesis buccal emergence profile design based on the buccal mucosal W/H ratio (Test Group)
Trial: 32557991
Drug: Low AM
RxNorm normalized name: Methionine,threonine,valine-free isoleucine-low amino acid mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low AM (200 mg/kg BW)
Trial: 32557991
Drug: Middle AM
RxNorm normalized name: wheat middlings extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Middle AM (400 mg/kg BW)
Trial: 32557991
Drug: High AM
RxNorm normalized name: hydroxypropyl distarch phosphate, high amylose corn
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High AM (800 mg/kg BW)
Trial: 32557991
Drug: CON (0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CON (0 mg/kg BW)
Trial: 35869267
Drug: Oral selinexor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral selinexor 60 mg twice weekly (days 1–24) with standard chemotherapy (3 + 7)
Trial: 35869267
Drug: Cytarabine 1000
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cytarabine 1000 mg/m2 twice daily, days 1–6 with selinexor
Trial: 35869267
Drug: Standard chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard chemotherapy (3 + 7) without selinexor
Trial: 33952438
Drug: Closed incision
RxNorm normalized name: INCISED NOTOPTERYGIUM RHIZOME OR ROOT (NOTOPTERYGIUM FRANCHETII)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Closed incision negative pressure wound therapy (NPWT)
Trial: 34260849
Drug: Bamlanivimab plus
RxNorm normalized name: Bamlanivimab
DrugBank: Bamlanivimab (DB15718)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bamlanivimab plus Etesevimab (2800 mg each, administered together)
Trial: 33587156
Drug: Cold atmospheric
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cold atmospheric plasma (CAP) treatment